Actively Recruiting

Age: 18Years - 75Years
All Genders
NCT06485271

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Led by Changzhi People's Hospital Affiliated to Changzhi Medical College · Updated on 2024-07-03

504

Participants Needed

1

Research Sites

152 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment

CONDITIONS

Official Title

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older, male or female
  • Diagnosed with advanced gastric cancer confirmed by pathology or histology
  • Patients with disease progression or recurrence after at least 6 months of adjuvant therapy may be included
  • At least one measurable lesion on imaging meeting RECIST 1.1 criteria (target lesion ≥10 mm or lymph node ≥15 mm)
  • Investigator agrees patient is suitable for treatment with camrelizumab or apatinib
  • Willing to enroll voluntarily, with good compliance and follow-up cooperation
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding women
  • Prior treatment with immunotherapy drugs such as PD-1, PD-L1, or CTLA4 monoclonal antibodies
  • Previous use of other anti-angiogenic agents including apatinib
  • Considered unsuitable for study inclusion by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Changzhi People's Hospital Affiliated to Changzhi Medical College

Changzhi, Shanxi, China

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here